What's breaking now, across thousands of outlets.
Roche’s T cell engager Lunsumio has passed a Phase 3 trial in a slow-growing type of blood cancer, clearing the path for full approval and a broader label. Lunsumio is a bispecific antibody that targets ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Deputy President Kithure Kindiki has revealed plans to transform Nyambene Level 4 Hospital into a major referral facility, with a Ksh100 million expansion expected to bring specialised medical…
A psychedelic-like drug for a Parkinson's symptom, mice with half-human brains, and more biotech news in the Readout newsletter.
Africa Intelligence Brief — Thursday, September 17, 2026 A health worker in protective equipment giving an Ebola vaccination in the Democratic Republic of the Congo.
